SCENESSE SIDE EFFECTS
- Generic Name: afamelanotide implant
- Brand Name: Scenesse
- Drug Class: Melanocortin Agonists
SIDE EFFECTS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of SCENESSE was evaluated in 3 randomized, multicenter, prospective, vehicle controlled clinical trials (Study CUV029, Study CUV030, and Study CUV039) involving 244 adult subjects with erythropoietic protoporphyria (EPP) without significant liver involvement. Subjects received subcutaneous SCENESSE implants containing 16 mg of afamelanotide every 2 months. A total of 125 subjects received SCENESSE and 119 subjects received vehicle implants.
Table 1 summarizes the adverse reactions that occurred in more than 2% of subjects.
Table 1: Adverse Reactions Occurring in More Than 2% of Subjects with EPP Through Month 6 (Studies CUV039, CUV030, and CUV029)
| Adverse Reaction | SCENESSE n (%) N = 125 |
Vehicle n (%) N = 119 |
| Implant site reaction1 | 26 (21%) | 12 (10%) |
| Nausea | 24 (19%) | 17 (14%) |
| Oropharyngeal pain | 9 (7%) | 6 (5%) |
| Cough | 8 (6%) | 4 (3%) |
| Fatigue | 7 (6%) | 3 (3%) |
| Skin hyperpigmentation2 | 5 (4%) | 0 (0%) |
| Dizziness | 5 (4%) | 4 (3%) |
| Melanocytic nevus | 5 (4%) | 2 (2%) |
| Respiratory tract infection | 5 (4%) | 3 (3%) |
| Somnolence | 3 (2%) | 1 (1%) |
| Non-acute porphyria | 2 (2%) | 0 (0%) |
| Skin irritation | 2 (2%) | 0 (0%) |
| 1 Implant site reaction includes: implant site bruising, discoloration, erythema, hemorrhage, hypertrophy, irritation, nodule, pain, pruritus, swelling; injection site bruising and erythema; and expelled implant. 2 Skin hyperpigmentation includes skin hyperpigmentation, pigmentation lip (subject also had skin hyperpigmentation), and pigmentation disorder. |
||
Specific Adverse Reactions
Implant Site Reactions
Implant site reactions were more common in the SCENESSE group (21%) compared to the vehicle group (10%). In the SCENESSE group, the most common implant site reaction was implant site discoloration (10%).
SRC: NLM .